Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ress in advancing programs within its late-stage development pipeline. These programs have significant potential to drive the company's growth beyond 2011.

Mozobil(TM) (plerixafor) for stem-cell transplantation

-- Genzyme plans to file mid year for U.S. and European approval for

Mozobil's use in treating patients with multiple myeloma and patients

with lymphoma. The company expects to launch the product in the United

States early next year upon approval and to rapidly expand the

product's availability around the world. The company anticipates peak

annual sales of the product in the transplant setting of $400 million.

Mozobil is an innovative product intended to enhance the mobilization

of stem cells for transplantation in patients with lymphoma and

multiple myeloma. In two pivotal clinical studies, Mozobil showed the

ability to quickly and predictably prepare cancer patients for a

transplant to treat their disease. Genzyme is also exploring

additional indications for Mozobil, including its potential use in

chemosensitization procedures.

Clolar for adult AML

-- Clolar is approved in the United States and Europe for the treatment of

acute lymphoblastic leukemia in relapsed and refractory pediatric

patients. Genzyme is developing the product for use globally as a

first-line therapy for the treatment of adult acute myeloid leukemia

(AML) and myelodysplastic syndromes, significantly larger indications

that the company estimates will drive peak annual sales of the product

to approximately $600 million. The company intends to submit a

supplemental new drug application in the United States later this year

to include an adult AML indication. This application will be based on

results from the CLASSIC II clinical trial involving older adult AML

<
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... May 15, 2012, JoVE ( Journal of Visualized ... United States government,s Defense Threat Reduction Agency (DTRA). ... University,s Dr. Chris Schafmeister and State University of New York ... The support of scientists conducting research for DTRA has significant ...
... Reportlinker.com announces that a new ... its catalogue: , Neuroendocrine Carcinoma ... Forecast to 2019 ... Therapeutics - Pipeline Assessment and Market ...
... BGI, one of the world,s largest genomics organizations, ... been successfully installed at its facility in Shenzhen, China. The ... sequencing technologies and enhance BGI,s long read sequencing capability. ... a Roche Company, features the unique combination of long reads, ...
Cached Biology Technology:JoVE partners with US government to publish cutting-edge defense research 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 2BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 3
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... prevalence of asthma, allergies and other chronic inflammatory disorders ... in part to their reduced exposure to the microbes ... scientific paper. , The article, published in the journal ... living in urban centers who have less access to ... inflammation, a condition caused by immune system dysfunction. , ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3
... A new study from researchers at Queen Mary, University of ... in self-managing their disease. People with diabetes have to ... their condition. This includes not only monitoring the level of ... restrictive diet but also social challenges such as negotiating relatives, ...
... N.Y. -- It turns out that the milk of human ... Research by psychologists at the University at Buffalo and ... part of the reason some people are kind and generous ... Poulin, PhD, assistant professor of psychology at UB, is the ...
... of the woodpecker,s resistance to head impact injury are ... group from the Key Laboratory for Biomechanics and Mechanobiology ... and Medical Engineering, Beihang University, and the School of ... out to study this problem. After 3 years of ...
Cached Biology News:Approach to diabetes self-management too narrow, study suggests 2Approach to diabetes self-management too narrow, study suggests 3Study finds peoples' niceness may reside in their genes 2Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
...
...
Biology Products: